Article
Molecular tumor board: molecularly adjusted therapy upon identification and functional validation of a novel ALK resistance mutation in a case of lung adenocarcinoma.
The oncologist - 17 Jan 2025
Arndt Annette, Neumann Christian, Riecke Armin, Bauer Arthur, Müller Matthias, Wölfle-Guter Manuela, Grunert Michael, Busch Hauke, Künstner Axel, von Bubnoff Nikolas, Fliedner Stephanie, Greinert Dina, Osius Jasmin, Nagarathinam Kumar, Steinestel Konrad, Gorantla Sivahari Prasad, Gebauer Niklas, Witte Hanno M
Abstract excerpt
We report a case of a long-term surviving patient with EML4/ALK translocated non-small cell adenocarcinoma of the lung in UICC8 stage IVA. During recurrence under continuous crizotinib therapy, a hitherto insufficiently characterized missense mutation in the ALK gene (Arg1181His) was identified through targeted sequencing. The aforementioned EML4/ALK translocation could still be detected in this situation....
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.